These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 33966319

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
    Arvanitakis A, Berntorp E, Astermark J.
    Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
    Kessler CM, Corrales-Medina FF, Mannucci PM, Jiménez-Yuste V, Tarantino MD.
    Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
    [Abstract] [Full Text] [Related]

  • 5. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users.
    McEneny-King A, Yeung CH, Edginton AN, Iorio A, Croteau SE.
    Haemophilia; 2020 Jan; 26(1):56-63. PubMed ID: 31742831
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton AN, Lillicrap D, Iorio A, Blanchette VS.
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [Abstract] [Full Text] [Related]

  • 8. Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.
    Delavenne X, Dargaud Y, Ollier E, Négrier C.
    Br J Clin Pharmacol; 2019 Apr; 85(4):771-781. PubMed ID: 30633808
    [Abstract] [Full Text] [Related]

  • 9. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
    Hua B, Lee A, Fan L, Li K, Zhang Y, Poon MC, Zhao Y.
    Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T.
    Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
    [Abstract] [Full Text] [Related]

  • 13. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
    Liesner RJ, Abraham A, Altisent C, Belletrutti MJ, Carcao M, Carvalho M, Chambost H, Chan AKC, Dubey L, Ducore J, Gattens M, Gresele P, Gruel Y, Guillet B, Jimenez-Yuste V, Kitanovski L, Klukowska A, Lohade S, Mancuso ME, Oldenburg J, Pavlova A, Pollio B, Sigaud M, Vdovin V, Vilchevska K, Wu JKM, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.
    Thromb Haemost; 2021 Nov; 121(11):1400-1408. PubMed ID: 33581698
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products.
    Megías-Vericat JE, Bonanad Boix S, Berrueco Moreno R, Mingot-Castellano ME, Rodríguez López M, Canaro Hirnyk M, Mateo Arranz J, Calvo Villas JM, Haya Guaita S, Mesegué Medà M, López Jaime F, Albo-López C, Palomero-Massanet A, Vilalta Seto N, Leciñena IL, Haro ARC, Poveda Andrés JL.
    Thromb Res; 2022 Aug; 216():35-42. PubMed ID: 35696967
    [No Abstract] [Full Text] [Related]

  • 18. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
    Cheng X, Li P, Chen Z, Zhang N, Zhen Y, Zhao L, Wang X, Wu R.
    Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
    [Abstract] [Full Text] [Related]

  • 19. Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
    Mathias M, Abashidze M, Abraham A, Belletrutti MJ, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Lambert T, Kavardakova N, Lohade S, Turea V, Wu JKM, Klukowska A.
    Haemophilia; 2023 Jul; 29(4):1005-1012. PubMed ID: 37335546
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.